Nutriband Inc.
NTRB Healthcare Biotechnology
Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025. In the quarter to July 2026, revenue fell 29.7%, EPS grew 96.7%, free cash flow grew 55.5% and total debt fell 46.9%, each against the same quarter a year earlier.
Follow NTRB
Nutriband Inc. (NTRB) Altman Z-score
Nutriband Inc.'s Altman Z-score for fiscal 2026 is 27.17, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | 27.17 | (12.66) |
| FY2025 | 39.83 | 35.35 |
| FY2024 | 4.48 | (12.07) |
| FY2023 | 16.55 | (0.71) |
| FY2022 | 17.25 | (2.17) |
| FY2021 | 19.43 | 6.84 |
| FY2020 | 12.59 | (210.09) |
| FY2019 | 222.68 | — |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.56 | — | 0.67 | |
| Retained earnings / total assets | (6.19) | — | −8.66 | |
| EBIT / total assets | (1.10) | — | −3.64 | |
| Market value of equity / total liabilities | 64.21 | — | 38.53 | |
| Sales / total assets | 0.27 | — | 0.27 | |
| Altman Z-score | Safe zone | 27.17 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −15.84 | ||
Z and Z″ put Nutriband Inc. in different zones: safe zone by Z, distress zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NTRB Nutriband Inc. | 27.2× |
| CLLS Cellectis S.A. compare | 0.0× |
| PTHS Pelthos Therapeutics Inc. compare | −0.8× |
| CRDF Cardiff Oncology, Inc. compare | −4.7× |
| PMN Promis Neurosciences compare | −78.9× |
| ACRV Acrivon Therapeutics, Inc. compare | — |
| TELO Telomir Pharmaceuticals, Inc. compare | — |
| OKYO OKYO Pharma Limited Sponsored ADR compare | — |
| PDSB PDS Biotechnology Corporation compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets